Nada Open Letter To All Manufacturers

John McEleney

首页> 外文期刊>AutoExec >Nada Open Letter To All Manufacturers

【24h】

Nada Open Letter To All Manufacturers

机译：Nada致所有制造商的公开信

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

On behalf ofrnAmerica's new carrnand truck dealers, Irnam writing to all thernauto manufacturersrnwho sell cars andrntrucks in thisrncountry to ask thatrnyou work more closely with your dealers. Specifically, werncall on you to conduct an immediate review of all policiesrnand other actions that affect dealers to determine whetherrnthey are still appropriate during this financial crisis in termsrnof flexibility, consistency, and fairness. While we believernyou are making sincere efforts to help dealers through thisrncrisis, we believe there are areas where every company canrnimprove. We must all work together to survive.

机译：Irnam代表美国新的卡尔南卡车经销商，写信给所有在该国出售汽车和卡车的汽车制造商，要求您与您的经销商更紧密地合作。具体来说，我们呼吁您立即审查所有影响经销商的政策和其他行动，以从灵活性，连贯性和公平性的角度确定在金融危机期间这些政策是否仍然合适。尽管我们相信您正在尽最大的努力来帮助经销商克服这场危机，但我们相信每家公司都可以在某些领域进行改进。我们必须共同努力才能生存。

著录项

来源
《AutoExec》 |2009年第3期|25|共1页
作者
John McEleney;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Current FDA-Related Drug Information New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval New Drug/Biologies License Applications Filed by Manufacturer Supplemental Actions Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2011,第9期

机译：当前与FDA有关的药物信息由FDA批准的新药物新剂型和适应症，由FDA代理商批准的待批FDA批准的新药/生物许可申请，由制造商提出的补充措施，由制造商提出的重要措施，或与“亲爱的健康专业人员”的信件有关安全
2. New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval New Drug/Biologies License Applications Filed by Manufacturer Supplemental Actions Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2011,第11期

机译：FDA批准的新药FDA批准前的FDA代理人批准的新剂型和适应症制造商提出的新药/生物许可申请由制造商提出的补充措施重大标签变更或与安全相关的“亲爱的健康专业人员”信函
3. Current FDA-Related Drug Information New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval New Drug/Biologies License Applications Filed by Manufacturer Supplemental Applications Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2010,第6期

机译：当前与FDA有关的药物信息由FDA批准的新药物，由FDA代理商批准的新剂型和适应症，待FDA批准的制造商提出的新药/生物许可申请，制造商提出的补充申请，重要的标签变更或与“亲爱的健康专业人员”的信件安全
4. Evaluation on Storm Surge along Suo-nada Sea, Japan [C] . Ayano Sonoda, Yoshihiko Ide, Masaru Yamashiro, International Ocean and Polar Engineering Conference;International Society of Offshore and Polar Engineers . 2020

机译：日本Suo-Nada Sea风暴浪涌评估
5. Un paso adelante, dos pasos atrás: la mujer española en insolación y nada [D] . Minogue, Sarah Elizabeth 2015

机译：前进一步，后退两步：中暑的西班牙女人，一无所有
6. An analysis of the warning letters issued by the FDA topharmaceutical manufacturers regarding misleading health outcomesclaims [O] . Satabdi Chatterjee, Harshali K. Patel, Sujit S. Sansgiry 2012

机译：FDA发出的警告信的分析制药商关于误导健康的结果要求
7. O novo Qualis, que não tem nada a ver com a ciência do Brasil: carta aberta ao presidente da CAPES The new Qualis, which has nothing to do with the science of Brazil: open letter to the president of CAPES [O] . Mauricio Rocha-e-Silva 2009

机译：新的Qualis，与巴西的科学无关：给CapEs总裁的公开信新的Qualis，与巴西的科学无关：致CapEs总裁的公开信
8. Letter from Chemical Manufacturers Assoc Responding to USEPA Letter dated 011090 Regarding Additional Information on the Dominant Lethal Study in Rats with Mbt with Attachment. [R] . 2000

机译：来自化学品制造商协会的回复UsEpa的信函011090关于附着物mbt的显性致死研究的附加信息。

Nada Open Letter To All Manufacturers

摘要

著录项

相似文献

相关主题

期刊订阅